Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

Electric Mind, a leading strategy and technology consultancy, announces its expansion into the United States with the opening of a new office in Chicago. This milestone marks a significant step in the ...

Key takeaways      While Generative AI (GenAI) technology continues to advance at incredible speed, organizational change has been hard work ? with more than two-thirds of respondents reporting that ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

2. DRI Healthcare Trust acquires royalty stake in Sebetralstat sales DRI Healthcare Trust, an affiliate of healthcare royalty PE firm DRI Capital, also announced in November that it acquired a ...

7. Sebetralstat for hereditary angioedema: By June 17, the U.S. market could have its first FDA-approved oral medication for the rare genetic health condition hereditary angioedema. The condition ...